rubeosis iridis
Information
- Disease name
- rubeosis iridis
- Disease ID
- DOID:14000
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00470977 | Completed | Phase 1/Phase 2 | Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy | May 2007 | December 2010 |
| NCT00557232 | Completed | Phase 4 | Intraocular Bevacizumab (Avastin) for Rubeosis Iridis | November 2006 | November 2011 |
| NCT01069341 | Completed | Phase 1 | Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery | July 2007 | January 2012 |
| NCT02641457 | Completed | Phase 3 | Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis | March 2014 | October 2015 |
- Disase is a (Disease Ontology)
- DOID:5679
- Cross Reference ID (Disease Ontology)
- ICD10CM:H21.1
- Cross Reference ID (Disease Ontology)
- ICD9CM:364.42
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:51995000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0154916
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0025319